Alan Levine Buys Shares of Axogen, Inc. Amid Strong Stock Performance
Insider Alan Levine acquired 14,150 shares of Axogen, Inc. on June 19.
Key Points
- Insider Alan Levine purchased 14,150 shares of Axogen, Inc. on June 19, with the stock trading at $44.95.
- Axogen, Inc. has a market cap of $2.39 billion and a forward P/E ratio of 61.7, with shares reaching a 52-week high of $45.83.
- Institutional investors like Morgan Stanley increased their holdings, while analysts maintain buy ratings with price targets around $50.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Alan Levine, an insider at Axogen, Inc., bought 14,150 shares of the company on June 19, 2026. This transaction did not involve a planned purchase, and it was reported under the code 'M'. The shares were acquired at no cost as part of a stock option exercise.
Other Institutional Activity in Axogen
Several institutional investors have recently adjusted their positions in Axogen. First Light Asset Management, LLC reduced its holdings by 1,230,558 shares, ending with 4,002,768 shares valued at approximately $132.6 million, marking a 23.5% decrease. Meanwhile, BlackRock, Inc. increased its stake by 151,414 shares, holding a total of 3,870,851 shares worth about $128.2 million, a 4.1% increase. Morgan Stanley also boosted its position by 536,112 shares to 3,122,982 shares valued at $103.5 million, reflecting a 20.7% rise. Vanguard Capital Management LLC opened a new position with 2,291,563 shares valued at $75.9 million, and Arrowmark Colorado Holdings LLC grew its holdings by 441,157 shares, reaching 1,915,439 shares worth $63.5 million, a 29.9% increase.
Axogen, Inc. Stock Down 13.2%
Shares of NasdaqCM:AXGN traded near $44.95 on Wednesday. Axogen, Inc. has a market capitalization of approximately $2.39 billion. The company, which operates in the medical devices industry, has a forward P/E ratio of 61.7 and a beta of 1.118. Over the past year, the stock has seen a low of $9.35 and a high of $45.83. It has a 50-day moving average of $40.43 and a 200-day moving average of $30.40. Axogen maintains a strong liquidity position with a current ratio of 7.101 and a quick ratio of 4.994, alongside a debt-to-equity ratio of 8.432.
$AXGN stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Axogen, Inc. reported revenue of $238.1 million, reflecting a growth rate of 26.6%. Despite this growth, the company posted a net margin of -13.2% and a return on equity of -17.96%. The company is not currently profitable, as indicated by its negative EPS of -0.64. Axogen is expected to release its next earnings report on August 4, 2026.
Insider Buying and Selling at Axogen, Inc.
On June 19, 2026, several insiders at Axogen, Inc. made notable stock purchases. Alan Levine, Wendell Amy McBride, Kathy Johnson Weiler, and Joseph Tyndall each bought 14,150 shares. Additionally, Paul Thomas acquired 18,867 shares. These transactions were not planned purchases.
Analysts Set New Price Targets
Several analysts have maintained their buy ratings on Axogen, Inc. On April 29, 2026, Canaccord Genuity, Citizens, and Wells Fargo all reaffirmed their buy ratings, with price targets of $50, $50, and $48, respectively. HC Wainwright & Co. also maintained a buy rating with a $50 target on the same date. The consensus among nine analysts is a buy rating, with a mean price target of $50.78.
About Axogen, Inc.
Axogen, Inc. is a healthcare company specializing in medical devices for peripheral nerve repair and regeneration. Based in Alachua, Florida, the company develops products like the Avance Nerve Graft and Axoguard Nerve Connector, which aid in the surgical repair of nerves. Axogen serves hospitals and surgery centers worldwide, focusing on surgeons in various specialties. The company, led by CEO Michael D. Dale, employs 622 people.
Bottom Line
Insider purchases like those by Alan Levine can be a sign of confidence in Axogen, Inc.'s prospects. The company's stock has performed well, nearing its 52-week high, while institutional investors and analysts remain engaged. Keep in mind that insider transactions are reported after they occur and may not reflect current holdings.
Get Axogen, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AXGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.